- Home
- DAVE vs CVAC Comparison
DAVE vs CVAC Comparison
Compare DAVE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- CVAC
- Stock Information
- Founded
- DAVE 2017
- CVAC 2000
- Country
- DAVE United States
- CVAC Germany
- Employees
- DAVE N/A
- CVAC N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- CVAC Health Care
- Exchange
- DAVE Nasdaq
- CVAC Nasdaq
- Market Cap
- DAVE 2.9B
- CVAC 764.4M
- IPO Year
- DAVE N/A
- CVAC 2020
- Fundamental
- Price
- DAVE $279.80
- CVAC $5.41
- Analyst Decision
- DAVE Strong Buy
- CVAC Hold
- Analyst Count
- DAVE 6
- CVAC 3
- Target Price
- DAVE $227.50
- CVAC $6.83
- AVG Volume (30 Days)
- DAVE 481.2K
- CVAC 2.2M
- Earning Date
- DAVE 08-04-2025
- CVAC 08-14-2025
- Dividend Yield
- DAVE N/A
- CVAC N/A
- EPS Growth
- DAVE N/A
- CVAC N/A
- EPS
- DAVE 3.70
- CVAC 0.87
- Revenue
- DAVE $381,425,000.00
- CVAC $566,039,775.00
- Revenue This Year
- DAVE $37.77
- CVAC N/A
- Revenue Next Year
- DAVE $17.77
- CVAC $24.04
- P/E Ratio
- DAVE $75.62
- CVAC $6.26
- Revenue Growth
- DAVE 39.31
- CVAC 787.60
- 52 Week Low
- DAVE $28.74
- CVAC $2.37
- 52 Week High
- DAVE $283.19
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- DAVE 73.24
- CVAC 64.13
- Support Level
- DAVE $252.01
- CVAC $5.33
- Resistance Level
- DAVE $280.31
- CVAC $5.45
- Average True Range (ATR)
- DAVE 16.78
- CVAC 0.08
- MACD
- DAVE 3.61
- CVAC -0.05
- Stochastic Oscillator
- DAVE 96.50
- CVAC 40.00
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.